• Exchange: Frankfurt
  • Sector: Health Care
  • Industry: Biotech & Pharma
  • Sub-Industry: Biotech

Rigel Pharmaceuticals Inc

+ Add to Watchlist

RI2A:GR

2.496 EUR 0.075 3.10%

As of 02:02:17 ET on 07/31/2014.

Snapshot for Rigel Pharmaceuticals Inc (RI2A)

Open: 2.496 Day's Range: 2.496 - 2.496 Volume: 0
Previous Close: 2.421 52wk Range: 1.684 - 3.491 1-Yr Rtn: -11.21%

Stock Chart for RI2A

No chart data available.
  • RI2A:GR 2.496
  • 1M
  • 1Y
2.421
Interactive RI2A Chart

Previous Close

No chart data available.
Interactive Chart
  • 1W
  • 1M
  • YTD
  • 1Y
  • 3Y
  • 5Y
Close:
Open:
High:
Low:
Volume:
Recently Viewed Symbols
Save as Watchlist
Saving as watchlist...

Key Statistics for RI2A

Current P/E Ratio (ttm) -
Estimated P/E(12/2014) -
Relative P/E vs. DAX -
Earnings Per Share (USD) (ttm) -
Est. EPS (USD) (12/2014) -1.0150
Est. PEG Ratio -
Market Cap (M EUR) 218.48
Shares Outstanding (M) 87.53
30 Day Average Volume 14
Price/Book (mrq) -
Price/Sale (ttm) -
Dividend Indicated Gross Yield -%
Cash Dividend -
Dividend Ex-Date
5 Year Dividend Growth -
Next Earnings Announcement 08/06/2014
mrq = Most Recent Quarter; ttm = Trailing Twelve Months

Income Statement for RI2A

  • Revenue
  • Net Income (M/USD)
  • Profit Margin (%)

Company Profile & Key Executives for RI2A

Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders. The Company's research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms.

James M GowerChairman/CEORaul R RodriguezPresident/COO
Ryan D MaynardExec VP/CFOElliott B GrossbardExec VP/Chief Medical Officer
More Company Profile & Key Executives for RI2A

Quotes delayed, except where indicated otherwise. All prices in local currency. Time is ET.

Sponsored Link
Advertisement
Advertisement
Sponsored Links
Advertisements
sec ||= nil